Table 2.
Clinical features and follow up data of 41 extra-uterine and extra-ovarian mullerian adenosarcoma according to histological features
| Total population | Endometriosis | P value | Overgrowth | P value | Heterologous sarcomatous differentiation | P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 41 n (%) | No n = 16 n (%) | Yes n = 25 n (%) | No n = 32 n (%) | Yes n = 9 n (%) | No n = 37 n (%) | Yes n = 4 n (%) | ||||
| Age (mean ± SD), years | 44.5 ± 15.0 | 43.1 ± 15.8 | 45.5 ± 12.7 | 0.597 | 45.4 ± 13.9 | 41.4 ± 14.6 | 0.463 | 46.4 ± 13.0 | 27.5 ± 11.8 | 0.009 |
| Size (mean ± SD), mm | 12.2 ± 6.9 | 13.4 ± 8.3 | 11.0 ± 5.3 | 0.319 | 12.5 ± 6.7 | 11.0 ± 8.1 | 0.659 | 11.9 ± 6.8 | 14.7 ± 8.5 | 0.517 |
| Site | 0.066 | 1 | 1 | |||||||
| Extra-genital | 32 (78.0) | 15 (93.8) | 17 (68.0) | 25 (78.1) | 7 (77.8) | 29 (78.4) | 3 (75.0) | |||
| Vagina | 9 (22.0) | 1 (6.2) | 8 (32.0) | 7 (21.9) | 2 (22.2) | 8 (21.6) | 1 (25.0) | |||
| Endometriosis | 1 | 0.281 | ||||||||
| No | 16 (39.0) | – | – | – | 13(40.6) | 3 (33.3) | 13 (35.1) | 3 (75.0) | ||
| Yes | 25 (61.0) | – | – | – | 19 (59.4) | 6 (66.7) | 24 (64.9) | 1 (25.0) | ||
| Overgrowth | 1 | 1 | ||||||||
| No | 32 (78.0) | 13 (81.3) | 19(76.0) | – | – | 29 (78.4) | 3 (75.0) | |||
| Yes | 9 (22.0) | 3 (18.7) | 6 (24.0) | – | – | 8 (21.6) | 1 (25.0) | |||
| Treatment | 0.557 | 1 | 0.101 | |||||||
| Surgery | 22 (53.7) | 9 (56.3) | 13 (52.0) | 18 (56.3) | 4 (44.4) | 19 (51.4) | 3 (75.0) | |||
| Surgery + additional treatments | 16 (39.0) | 5 (31.2) | 11 (44.0) | 11 (34.4) | 5 (55.6) | 16 (43.2) | 0 (0.0) | |||
| No Surgery | 3 (7.3) | 2 (12.5) | 1(4.0) | 3 (9.4) | 0 (0.0) | 2 (5.4) | 1 (25.0) | |||
| Surgical Approach | 0.345 | 1 | 0.327 | |||||||
| Complete resection | 33 (80.5) | 11 (68.8) | 22 (88.0) | 25 (78.1) | 8 (88.9) | 30 (81.1) | 3 (75.0) | |||
| Partial resection | 5 (12.2) | 3 (18.7) | 2 (8.0) | 4 (12.5) | 1 (11.1) | 5 (13.5) | 0 (0.0) | |||
| No surgery | 3 (7.3) | 2 (12.5) | 1 (4.0) | 3 (9.4) | 0 (0.0) | 2 (5.4) | 1 (25.0) | |||
| Lost in follow up | 6 (14.6) | 4 | 2 | 4 | 2 | 6 | 0 | |||
| Status at last follow up (35 patients) | 0.002 | 0.843 | 0.278 | |||||||
| FOD | 22 (62.9) | 3 (25.0) | 19 (82.6) | 17 (60.7) | 5 (71.4) | 19 (61.3) | 3 (75.0) | |||
| AWD | 4 (11.4) | 3 (50.0) | 1 (4.3) | 4 (14.3) | 0 (0.0) | 3 (9.7) | 1 (25.0) | |||
| DOD | 9 (25.7) | 6 (25.0) | 3 (13.0) | 7 (25.0) | 2 (28.6) | 9 (29.0) | 0 (0.0) | |||
| Recurrence | 18 (51.4) | 9 (56.2) | 9 (36.0) | 0.184 | 13 (40.6) | 5 (55.5) | 0.447 | 15 (45.5) | 3 (75.0) | 0.340 |
| More than 1 recurrence | 9 (25.7) | 4 (28.6) | 5 (21.7) | 1 | 5 (17.9) | 4 (57.1) | 0.294 | 7 (18.9) | 2 (50.0) | 1 |
| Death patients OS (mean ± sd) | 7.0 ± 5.7 | 46.3 ± 63.9 | 0.151 | 6.0 ± 4.0 | 16.7 ± 17.8 | 0.179 | 20.1 ± 37.8 | – | * | |
| Patients with recurrence DFS (mean ± sd) | 47.9 ± 63.6 | 28.0 ± 41.3 | 0.486 | 12.2 ± 11.4 | 11.4 ± 12.6 | 0.897 | 11.9 ± 12.1 | 11.6 ± 10.5 | 1 | |
AWD alive with disease, DOD died of disease, FOD free of disease
*comparison was not possible, because no patients with heterologous sarcomatous differentiation dead during follow up